DMAQ
Deep Medicine Acquisition
DMAQ | NASDAQ
$2.96
-$5.43 (-64.72%)
At close: Jan 31, 2024, 04:00 PM ET
Deep Medicine Acquisition Company Profile
Company profile explainedCompany Profile
Deep Medicine Acquisition Corp. (DMAQ) currently operates as a non-operating entity, possessing no substantial business functions of its own. Its express purpose is to execute a business combination, which could entail a merger, an acquisition of equity or assets, or a reorganization, with one or more target companies. The firm's strategic efforts are specifically concentrated on identifying promising enterprises within the healthcare industry. Incorporated in 2020, DMAQ maintains its principal place of business in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Humphrey Polanen | Chief Executive Officer & Chairman of the Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 29, 2026 | 8-K | Current Report |
| Sep 24, 2026 | 8-K | Current Report |
| Sep 09, 2026 | 8-K | Current Report |
| Aug 27, 2026 | 8-K | Current Report |
| Aug 24, 2026 | 8-K | Current Report |
| Aug 21, 2026 | 8-K | Current Report |
| Aug 18, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| May 22, 2026 | 3 | Filing |
| May 20, 2026 | 10-Q | Quarterly Report |
Deep Medicine Acquisition
DMAQ
| Country | United States |
| IPO Date | Dec 2, 2021 |
| Industry | Shell Companies |
| Sector | Financial Services |
| Employees | 2 |
| CEO | Humphrey P. Polanen |
Stock Details
| Ticker Symbol | DMAQ |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001857086 |
| CUSIP Number | 243733102 |
| ISIN Number | US2437331026 |
| SIC Code | 6770 |
Add to Watchlist
Select watchlists to add or remove DMAQ